Alimentary Pharmacology & Therapeutics

The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine
pp. 1699-1708(10)
Authors: Nielsen, O. H.; Vainer, B.; Rask-Madsen, J.

The immunoregulatory cytokine interleukin-10—a therapy for Crohn's disease?
pp. 1709-1716(8)
Authors: Lindsay, J. O.; Hodgson, H. J. F.

The pharmacological treatment of acute colonic pseudo-obstruction
pp. 1717-1727(11)
Authors: De Giorgio, R.; Barbara, G.; Stanghellini, V.; Tonini, M.; Vasina, V.; Cola, B.; Corinaldesi, R.; Biagi, G.; De Ponti, F.

Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis
pp. 1729-1736(8)
Authors: Edwards, S. J.; Lind, T.; Lundell, L.

Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection
pp. 1737-1744(8)
Authors: Tsang, S. W. C.; Chan, H. L. Y.; Leung, N. W. Y.; Chau, T. N.; Lai, S. T.; Chan, F. K. L.; Sung, J. J. Y.

Tegaserod, a 5-HT₄ receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects
pp. 1745-1751(7)
Authors: Degen, L.; Matzinger, D.; Merz, M.; Appel-Dingemanse, S.; Osborne, S.; Lüchinger, S.; Bertold, R.; Maecke, H.; Beglinger, C.

Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with Helicobacter pylori infection
pp. 1753-1761(9)
Authors: Capurso, G.; Lahner, E.; Marcheggiano, A.; Caruana, P.; Carnuccio, A.; Bordi, C.; Delle Fave, G.; Annibale, B.

Citric acid-enhanced Helicobacter pylori urease activity in vivo is unrelated to gastric emptying
pp. 1763-1767(5)
Authors: Shiotani, A.; Saeed, A.; Yamaoka, Y.; Osato, M. S.; Klein, P. D.; Graham, D. Y.

Lack of symptom benefit following presumptive Helicobacter pylori eradication therapy in primary care
pp. 1769-1775(7)
Authors: Williams, D.; O'Kelly, P.; Kelly, A.; Feely, J.

Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan
pp. 1777-1785(9)
Authors: Ikeda, S.; Tamamuro, T.; Hamashima, C.; Asaka, M.

A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia
pp. 1787-1793(7)
Authors: Laurent, J.; Mégraud, F.; Fléjou, J. F.; Caekaert, A.; Barthélemy, P.

Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study
pp. 1795-1806(12)
Authors: Hirschowitz, B. I.; Simmons, J.; Mohnen, J.

A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH
pp. 1807-1817(11)
Authors: Täubel, J. J.; Sharma, V. K.; Chiu, Y. L.; Lukasik, N. L.; Pilmer, B. L.; Pan, W. J.

Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa
pp. 1819-1826(8)
Authors: Geboes, K.; Dekker, W.; Mulder, C. J. J.; Nusteling, K.

Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model
pp. 1827-1836(10)
Authors: Colpaert, S.; Liu, Z.; De Greef, B.; Rutgeerts, P.; Ceuppens, J. L.; Geboes, K.

A study of the effects of indometacin on liver mitochondria from rats, mice and humans
pp. 1837-1842(6)
Authors: Jacob, M.; Bjarnason, I.; Rafi, S.; Wrigglesworth, J.; Simpson, R. J.